13F filer · CIK 1352851 ↗
Magnetar Financial LLC
You are looking at Q3 2024. See the latest, Q2 2026 →
Reported value
$4.62B
−3.7% on the quarter before
Positions
507
273 new · 263 sold out
Top 10
20.6%
of the value
Est. gain
+$68.7M
on stocks held all quarter
Est. return
+2.8%
on those stocks since Q2 2024
Positions as of Sep 30, 2024, from Magnetar Financial LLC's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 42% of the reported value, each sized by its share, colored by what the fund did with it since Q2 2024. Striped tiles are options.
Largest buys
Since Q2 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Kellanova~$80.5MNew · 0.0% → 1.7%+997,792 shares
- Mckesson Corp~$48.8MAdded · 0.8% → 1.7%+98,616 shares
- Frontier Communications Pare~$46.8MNew · 0.0% → 1.0%+1,316,693 shares
- Tellurian Inc New~$46.7MNew · 0.0% → 1.0%+48,258,000 shares
- Sarepta Therapeutics Inc~$40.6MNew · 0.0% → 0.9%+35,710,000 shares
- Sea~$40.4MAdded · 0.2% → 1.1%+33,700,000 shares
- Boston Scientific Corp~$40.4MAdded · 0.6% → 1.6%+481,989 shares
- Astrazeneca Plc~$37.4MNew · 0.0% → 0.8%+480,000 shares
- Vishay Intertechnology~$36.6MNew · 0.0% → 0.8%+39,930,000 shares
- Teleflex Incorporated~$34.6MAdded · 0.3% → 1.1%+139,847 shares
Largest sells
Since Q2 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Novartis Ag~$139.0MSold out · 2.9% → 0.0%−1,305,446 shares
- Zimmer Biomet Holdings Inc~$123.5MCut · 3.0% → 0.4%−1,144,448 shares
- Becton Dickinson & Co~$89.5MCut · 2.6% → 0.8%−371,052 shares
- Churchill Capital Corp Vii~$89.5MSold out · 1.9% → 0.0%−8,306,005 shares
- Abbott Labs~$88.9MCut · 1.7% → 0.0%−779,820 shares
- Solventum Corp~$87.2MCut · 1.6% → 0.4%−1,250,428 shares
- Westrock Co~$83.4MSold out · 1.7% → 0.0%−1,658,921 shares
- Unitedhealth Group Inc~$74.3MCut · 1.7% → 0.4%−127,000 shares
- Silk Rd Med Inc~$53.3MSold out · 1.1% → 0.0%−1,970,373 shares
- Olink Hldg Ab~$52.0MSold out · 1.1% → 0.0%−2,040,732 shares
Holdings
As of Sep 30, 2024. Changes are in shares against Jun 30, 2024, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health IncCOM · shares +27% · price +1.8% | 3.4% | $155.4M | +$2.2M | ||||||||
| Globus MedicalCL A · shares −17% · price +4.5% | 2.2% | $102.5M | +$4.4M | ||||||||
| SanofiSPONSORED ADR · shares −35% · price +18.8% | 2.0% | $94.2M | +$14.9M | ||||||||
| Juniper Networks IncCOM · shares +1.7% · price +6.9% | 2.0% | $92.1M | +$5.9M | ||||||||
| Stericycle IncCOM · shares +4.6% · price +4.9% | 1.9% | $89.6M | +$4.0M | ||||||||
| Southwestern Energy CoCOM · shares +4.6% · price +5.6% | 1.9% | $88.3M | +$4.5M | ||||||||
| The Cigna GroupCOM · shares +31% · price +4.8% | 1.9% | $86.0M | +$3.0M | ||||||||
| Axonics IncCOM · shares +4.3% · price +3.5% | 1.8% | $82.8M | +$2.7M | ||||||||
| Mckesson CorpCOM · shares +153% · price −15.3% | 1.7% | $80.5M | −$5.8M | ||||||||
| KellanovaCOM · shares New | 1.7% | $80.5M | — | ||||||||
| Discover Finl SvcsCOM · shares +4.4% · price +7.2% | 1.7% | $80.1M | +$5.2M | ||||||||
| Thermo Fisher Scientific IncCOM · shares +39% · price +11.9% | 1.7% | $79.6M | +$6.0M | ||||||||
| Johnson & JohnsonCOM · shares −13% · price +10.9% | 1.7% | $78.2M | +$7.7M | ||||||||
| Hashicorp IncCOM CL A · shares +4.6% · price +0.5% | 1.6% | $75.1M | +$360,737 | ||||||||
| Albertsons Cos IncCOMMON STOCK · shares +3.4% · price −6.4% | 1.6% | $74.9M | −$5.0M | ||||||||
| Boston Scientific CorpCOM · shares +124% · price +8.8% | 1.6% | $73.0M | +$2.6M | ||||||||
| Ansys IncCOM · shares +4.3% · price −0.9% | 1.5% | $69.4M | −$599,363 | ||||||||
| Championx CorporationCOM · shares +4.6% · price −9.2% | 1.5% | $69.2M | −$6.7M | ||||||||
| Cooper Cos IncCOM · shares −19% · price +26.4% | 1.4% | $65.2M | +$13.6M | ||||||||
| Catalent IncCOM · shares +4.4% · price +7.7% | 1.4% | $63.0M | +$4.3M | ||||||||
| Heartland Finl Usa IncCOM · shares +4.7% · price +27.6% | 1.3% | $62.3M | +$12.8M | ||||||||
| Marathon Oil CorpCOM · shares +4.6% · price −7.1% | 1.3% | $61.8M | −$4.5M | ||||||||
| Amedisys IncCOM · shares +3.3% · price +5.1% | 1.3% | $61.3M | +$2.9M | ||||||||
| Wayfair IncNOTE 3.500%11/1 · shares +21% · price +6.0% | 1.3% | $60.5M | — | ||||||||
| Option Care Health IncCOM NEW · shares −23% · price +13.0% | 1.3% | $59.8M | +$6.9M | ||||||||
| Total · 507 positions | 100% | $4.62B | +$68.7M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2024 to Q3 2024: 207 stocks held throughout, up $68.7M (+2.8%).
- Sanofi+$14.9M+19%
- Cooper Cos Inc+$13.6M+26%
- Heartland Finl Usa Inc+$12.8M+28%
- Wheeler Real Estate Invt Tr+$8.7M+64%
- Johnson & Johnson+$7.7M+11%
- Albertsons Cos Inc−$5.0M−6%
- Alphatec Hldgs Inc−$5.1M−47%
- Mckesson Corp−$5.8M−15%
- Championx Corporation−$6.7M−9%
- Adma Biologics Inc1:93 split−$40.7M−98%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 1 split read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $10.96B+11% | SEC ↗ |
| Q1 2026 | May 13, 2026 | $9.84B−4% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $10.21B−38% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $16.50B−20% | SEC ↗ |
| Q2 2025 | Aug 12, 2025 | $20.65B+171% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $7.61B+75% | SEC ↗ |
| Q4 2024 | Feb 11, 2025 | $4.36B−6% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $4.62B−4% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $4.80B+7% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $4.47B+13% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $3.94B+1% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $3.92B−14% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $4.56B−11% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $5.13B−13% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $5.91B−18% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $7.21B−25% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $9.67B+3% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $9.37B−6% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $9.96B+1% | SEC ↗ |
| Q3 2021 | Jan 14, 2022 (amended) | $9.82B−7% | SEC ↗ |
| Q2 2021 | Aug 6, 2021 | $10.56B+2% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $10.40B+47% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $7.08B+25% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $5.66B+67% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $3.39B−18% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $4.15B−13% | SEC ↗ |
| Q4 2019 | Feb 13, 2020 | $4.79B+22% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $3.93B−21% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $5.00B+29% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $3.89B−5% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $4.08B−26% | SEC ↗ |
| Q3 2018 | Feb 14, 2019 (amended) | $5.54B−16% | SEC ↗ |
| Q2 2018 | Aug 14, 2018 (amended) | $6.56B+13% | SEC ↗ |
| Q1 2018 | May 15, 2018 (amended) | $5.80B+3% | SEC ↗ |
| Q4 2017 | Feb 14, 2018 (amended) | $5.62B+2% | SEC ↗ |
| Q3 2017 | Nov 14, 2017 (amended) | $5.52B−15% | SEC ↗ |
| Q2 2017 | Aug 14, 2017 (amended) | $6.52B−7% | SEC ↗ |
| Q1 2017 | May 15, 2017 (amended) | $7.02B+1,897% | SEC ↗ |
| Q4 2016 | Aug 14, 2017 (amended) | $351.5M−95% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 (amended) | $7.03B+17% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 (amended) | $6.02B−7% | SEC ↗ |
| Q1 2016 | May 16, 2016 (amended) | $6.49B | SEC ↗ |